Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress

References

• Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med 2008;8:609–619.
   PubMed Web of Science ®Google Scholar
• Prus E, Fibach E. Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells. Acta Haematol 2010;123:14–20.
   PubMed Web of Science ®Google Scholar
• Han YH, Kim SU, Kwon TH, Lee DS, Ha HL, Park DS, et al.Peroxiredoxin II is essential for preventing hemolytic anemia from oxidative stress through maintaining hemoglobin stability. Biochem Biophys Res Commun 2012;426:427–432.
   PubMed Web of Science ®Google Scholar
• Manta B, Hugo M, Ortiz C, Ferrer-Sueta G, Trujillo M, Denicola A. The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2. Arch Biochem Biophys 2009;484:146–154.
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Bertoldi M, De Falco L, Santos Franco S, Ronzoni L, Turrini F, et al.Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in beta-thalassemic erythropoiesis. Haematologica 2011;96:1595–1604.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Yodoi J. Extracellular thioredoxin: a therapeutic tool to combat inflammation. Cytokine Growth Factor Rev 2013;24:345–353.
   PubMedGoogle Scholar
• Mahmood DF, Abderrazak A, El Hadri K, Simmet T, Rouis M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal 2013;19: 1266–1303.
   PubMed Web of Science ®Google Scholar
• Ho YS, Xiong Y, Ma W, Spector A, Ho DS. Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury. J Biol Chem 2004;279:32804–32812.
   PubMed Web of Science ®Google Scholar
• Ho YS, Magnenat JL, Bronson RT, Cao J, Gargano M, Sugawara M, Funk CD. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. J Biol Chem 1997;272:16644–16651.
   PubMed Web of Science ®Google Scholar
• de Haan JB, Bladier C, Griffiths P, Kelner M, O’Shea RD, Cheung NS, et al.Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide. J Biol Chem 1998;273: 22528–22536.
   PubMed Web of Science ®Google Scholar
• Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, et al.Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood 2003;101:5033–5038.
   PubMed Web of Science ®Google Scholar
• Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Clin Biochem 1986;24:481–495.
   PubMedGoogle Scholar
• Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1). J Clin Chem Clin Biochem 1986;24:497–510.
   PubMedGoogle Scholar
• Eda S, Kaufmann J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 1998;12:137–144.
   PubMed Web of Science ®Google Scholar
• Olivieri O, De Franceschi L, Capellini MD, Girelli D, Corrocher R, Brugnara C. Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias. Blood 1994;84:315–320.
   PubMed Web of Science ®Google Scholar
• Amer J, Goldfarb A, Fibach E. Flow cytometric measurement of reactive oxygen species production by normal and thalassaemic red blood cells. Eur J Haematol 2003;70:84–90.
   PubMed Web of Science ®Google Scholar
• Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and satisfaction with deferasirox (Exjade) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology 2013;19:187–191.
   PubMedGoogle Scholar
• Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, et al.Relationship among chelator adherence, change in chelators, and quality of life in Thalassemia. Qual Life Res 2014;23:2277–2288.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Britton RS. Hepatic injury in chronic iron overload. Role of lipid peroxidation. Chem Biol Interact 1989;70:183–226.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al.Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107: 3738–3744.
   PubMed Web of Science ®Google Scholar
• Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, et al.Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 2008;93:817–825.
   PubMed Web of Science ®Google Scholar
• Hofer S, Rosenhagen C, Nakamura H, Yodoi J, Bopp C, Zimmermann JB, et al.Thioredoxin in human and experimental sepsis. Crit Care Med 2009;37:2155–2159.
   PubMedGoogle Scholar
• Abdiu A, Nakamura H, Sahaf B, Yodoi J, Holmgren A, Rosen A. Thioredoxin blood level increases after severe burn injury. Antioxid Redox Signal 2000;2:707–716.
   PubMed Web of Science ®Google Scholar
• Detchaporn P, Kukongviriyapan U, Prawan A, Jetsrisuparb A, Greenwald SE, Kukongviriyapan V. Altered vascular function, arterial stiffness, and antioxidant gene responses in pediatric thalassemia patients. Pediatr Cardiol 2012;33:1054–1060.
   PubMed Web of Science ®Google Scholar
• Naithani R, Chandra J, Bhattacharjee J, Verma P, Narayan S. Peroxidative stress and antioxidant enzymes in children with beta-thalassemia major. Pediatr Blood Cancer 2006;46: 780–785.
   PubMed Web of Science ®Google Scholar
• Meral A, Tuncel P, Surmen-Gur E, Ozbek R, Ozturk E, Gunay U. Lipid peroxidation and antioxidant status in beta-thalassemia. Pediatr Hematol Oncol 2000;17:687–693.
   PubMed Web of Science ®Google Scholar
• Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, et al.Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996;88:3608–3614.
   PubMed Web of Science ®Google Scholar
• Suttnar J, Cermak J, Dyr JE. Solid-phase extraction in malondialdehyde analysis. Anal Biochem 1997;249:20–23.
   PubMedGoogle Scholar
• Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, et al.Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305–310.
   PubMed Web of Science ®Google Scholar
• Amer J, Atlas D, Fibach E. N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells. Biochim Biophys Acta 2008;1780:249–255.
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Adly AA, Attia AA, Ibrahim FA, Mohammed AS, Sayed AM. Effect of antioxidant therapy on hepatic fibrosis and liver iron concentrations in beta-thalassemia major patients. Hemoglobin 2013;37:257–276.
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Bertoldi M, Matte A, Santos Franco S, Pantaleo A, Ferru E, Turrini F. Oxidative stress and beta-thalassemic erythroid cells behind the molecular defect. Oxid Med Cell Longev 2013;2013:985210.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Saha S, Basu S, Chakravarty S, Chakravarty A, Banerjee D, Chakrabarti A. Differential regulation of redox proteins and chaperones in HbEbeta- thalassemia erythrocyte proteome. Proteomics Clin Appl 2010;4:480–488.
   PubMed Web of Science ®Google Scholar
• Low FM, Hampton MB, Peskin AV, Winterbourn CC. Peroxiredoxin 2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in the erythrocyte. Blood 2007;109: 2611–2617.
   PubMed Web of Science ®Google Scholar
• Lopert P, Day BJ, Patel M. Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS One 2012;7:e50683.
   Google Scholar
• Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A, Goodman SR. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol 2003;73:26–32.
   PubMed Web of Science ®Google Scholar
• Nur E, Brandjes DP, Teerlink T, Otten HM, Oude Elferink RP, Muskiet F, et al.N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann Hematol 2012;91:1097–1105.
   PubMed Web of Science ®Google Scholar